Mass Spectrometry-Based Metabolomics in Health and Disease: Targeted Analysis

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Advances in Metabolomics".

Deadline for manuscript submissions: closed (25 October 2024) | Viewed by 1158

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences, Alma Mater Studiorum—University of Bologna, 40138-Bologna, Italy
Interests: chromatography; mass spectrometry; biomarker identification

Special Issue Information

Dear Colleagues,

Metabolomics is a fascinating and growing field that aims to identify and quantify small molecules derived from cell and body metabolism. Biomarker discovery, drug discovery, toxicological testing, and clinical and preclinical studies are areas in which metabolomics plays a key role.

The nature of the metabolites, particularly their complexity and heterogeneity, the dynamic range of the measurement technique, the extraction protocols, and the myriad of variables related to the variation in these metabolites, remains as the main challenge. However, metabolomics is a very powerful approach for the characterisation of metabolites and metabolic pathways in health and disease, reflecting the results of the complex network of biochemical reactions that occur in living systems. Here, chromatography coupled with mass spectrometry (MS)-based metabolomics is the gold standard due to its beneficial bioanalytic performance characteristics such as high selectivity and high sensitivity, providing innovative tools for novel diagnostic and prognostic approaches. In this context, targeted analysis is key to analyse measurable metabolites in biological samples or a set of preselected metabolites. However, many challenges need to be overcome, including the proper validation of methods, sample selection and quality control, and complex statistical data analysis. Therefore, new mass spectrometry-based metabolomics methods and the discovery of interesting biomarkers are the main targets of this Special Issue.

Dr. Emanuele Porru
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mass spectrometry
  • metabolomics
  • metabolic diseases
  • chromatography
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1894 KiB  
Article
Alterations in Choline Metabolism in Non-Obese Individuals with Insulin Resistance and Type 2 Diabetes Mellitus
by Haya Al-Sulaiti, Najeha Anwardeen, Sara S. Bashraheel, Khaled Naja and Mohamed A. Elrayess
Metabolites 2024, 14(8), 457; https://doi.org/10.3390/metabo14080457 - 18 Aug 2024
Viewed by 910
Abstract
The prevalence of non-obese individuals with insulin resistance (IR) and type 2 diabetes (T2D) is increasing worldwide. This study investigates the metabolic signature of phospholipid-associated metabolites in non-obese individuals with IR and T2D, aiming to identify potential biomarkers for these metabolic disorders. The [...] Read more.
The prevalence of non-obese individuals with insulin resistance (IR) and type 2 diabetes (T2D) is increasing worldwide. This study investigates the metabolic signature of phospholipid-associated metabolites in non-obese individuals with IR and T2D, aiming to identify potential biomarkers for these metabolic disorders. The study cohort included non-obese individuals from the Qatar Biobank categorized into three groups: insulin sensitive, insulin resistant, and patients with T2D. Each group comprised 236 participants, totaling 708 individuals. Metabolomic profiling was conducted using high-resolution mass spectrometry, and statistical analyses were performed to identify metabolites associated with the progression from IS to IR and T2D. The study observed significant alterations in specific phospholipid metabolites across the IS, IR, and T2D groups. Choline phosphate, glycerophosphoethanolamine, choline, glycerophosphorylcholine (GPC), and trimethylamine N-oxide showed significant changes correlated with disease progression. A distinct metabolic signature in non-obese individuals with IR and T2D was characterized by shifts in choline metabolism, including decreased levels of choline and trimethylamine N-oxide and increased levels of phosphatidylcholines, phosphatidylethanolamines, and their degradation products. These findings suggest that alterations in choline metabolism may play a critical role in the development of glucose intolerance and insulin resistance. Targeting choline metabolism could offer potential therapeutic strategies for treating T2D. Further research is needed to validate these biomarkers and understand their functional significance in the pathogenesis of IR and T2D in non-obese populations. Full article
Show Figures

Figure 1

Back to TopTop